Head to Head Contrast: Nyxoah (NASDAQ:NYXH) versus Butterfly Network (NYSE:BFLY)

Butterfly Network (NYSE:BFLY) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Butterfly Network and Nyxoah, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1	2	3	0	2.33
Nyxoah	1	1	2	0	2.25

Butterfly Network presently has a consensus price target of $5.56, indicating a potential upside of 46.19%. Nyxoah has a consensus price target of $7.67, indicating a potential upside of 148.92%. Given Nyxoah’s higher possible upside, analysts clearly believe Nyxoah is more favorable than Butterfly Network.

Insider and Institutional Ownership

37.8% of Butterfly Network shares are held by institutional investors. 25.2% of Butterfly Network shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Butterfly Network has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.

Earnings & Valuation

This table compares Butterfly Network and Nyxoah”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$102.92 million	9.41	-$77.06 million	($0.30)	-12.68
Nyxoah	$11.33 million	10.54	-$101.92 million	($2.48)	-1.24

Butterfly Network has higher revenue and earnings than Nyxoah. Butterfly Network is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Butterfly Network and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
Nyxoah	-543.21%	-163.73%	-80.24%

Summary

Butterfly Network beats Nyxoah on 11 of the 14 factors compared between the two stocks.

About Butterfly Network

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.